In Vivo P-31 -MR-Spectroscopy of Focal Hepatic Lesions

Brinkmann, G.; Melchert, Uwe H.; Emde, Lars; Wolf, H.; Mühle, Claus; Brossmann, Joachim; Reuter, M.; Heller, Martin

doi:10.1097/00004424-199501000-00009

Cited by 9 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may not be excluded that different histological features of the disease may be able to explain the reported differences in HEP relative content. In fact, increased PME ratios have been repeatedly found in patients with more severe liver diseases including chronic hepatitis C [26], liver cirrhosis [27], or tumors [28], all conditions in which extensive membrane remodeling may have an effect on the membrane phosphocholine and phosphoethanolamine kinetics and ultimately in PME content.…”

Section: Discussionmentioning

confidence: 99%

Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver

Lattuada¹,

Radaelli²,

Cobelli

et al. 2019

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background. Fatty liver is believed to be sustained by a higher than normal adipose-derived NEFA flux to the liver. Also, hepatic energy metabolism may be a rate-limiting step of intrahepatic fat (IHF) accumulation. Aims. To assess whole-body energy metabolism and hepatic high-energy phosphates (HEPs) in individuals with fatty liver. Methods. We studied 22 individuals with fatty liver and 22 control individuals matched for anthropometric features by means of (1) hepatic 1H-magnetic resonance spectroscopy (MRS) to measure the IHF content, (2) hepatic 31P-MRS to assess the relative content of HEPs (phosphomonoesters, phosphodiesters, inorganic phosphorus, and ATP), and (3) indirect calorimetry to assess whole-body resting energy expenditure and substrate oxidation. Results. Patients with newly diagnosed fatty liver and controls were not different for anthropometric parameters. Based on HOMA2%-S, individuals with fatty liver were more insulin resistant than controls. Resting energy expenditure and the pattern of substrate oxidation were not different between groups. Relative content of HEPs was not different between groups; in particular, the Pi/γ-ATP ratio, the most important signals in terms of monitoring energy homeostasis, was not different even if it was associated with indirect calorimetry-derived parameters of oxidative substrate disposal. Conclusions. These data demonstrate that fasting whole-body energy metabolism and the relative content of HEPs in nondiabetic patients with fatty liver are not different than those in controls when they are matched for anthropometric features.

show abstract

Section: Discussionmentioning

confidence: 99%

Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver

Lattuada¹,

Radaelli²,

Cobelli

et al. 2019

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…The current review provides an overview of quantitative 31 P MRS data in liver cancer. In liver cancer, substantial alterations in levels of 31 P metabolites involved in cell proliferation and energy metabolism have been observed. In particular, liver tumors were associated with an elevation of PME/PDE and PME/Pi compared to healthy liver tissue, although there was a broad variety among studies.…”

Section: Discussionmentioning

confidence: 99%

“…35 To be able to directly compare the results from the different studies, we therefore calculated relative differences/changes in the reported 31 P metabolite levels/ratios. Table 2 shows relative differences in 31 P metabolite levels or metabolic ratios in patients before therapy and healthy volunteers in the same study. For each metabolite or metabolic ratio, there was data available from at least two studies out of the seven eligible studies.…”

Section: P Metabolite Levels In Liver Cancermentioning

confidence: 99%

“…An increased PME/PDE ratio, indicative of cell proliferation, is a characteristic feature of tumor tissue and a reduction in PME/PDE during therapy has been demonstrated to be a marker of therapy response in breast cancer. [22][23][24] Importantly, changes in 31 P metabolites during treatment have been shown to take place well before morphological changes can be observed. 25-27 31 P MRS could thus possibly be of help to assess effects of therapy for pancreatic and liver cancer in an early stage, thereby optimizing treatment efficacy and reducing unnecessary side effects of ineffective treatments.…”

mentioning

confidence: 99%

“…The aim of this systematic review is to conduct a quantitative analysis of the available literature on 31 P MRS performed in hepatopancreatobiliary cancer and to provide insight into the current status of 31 P MRS and its potential for therapy (non-)response assessment.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prospective of ³¹P MR Spectroscopy in Hepatopancreatobiliary Cancer: A Systematic Review of the Literature

Seelen

Wildenberg

Kemp

et al. 2022

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background: The incidence of liver and pancreatic cancer is rising. Patients benefit from current treatments, but there are limitations in the evaluation of (early) response to treatment. Tumor metabolic alterations can be measured noninvasively with phosphorus ( 31 P) magnetic resonance spectroscopy (MRS). Purpose: To conduct a quantitative analysis of the available literature on 31 P MRS performed in hepatopancreatobiliary cancer and to provide insight into its current and potential for therapy (non-) response assessment. Population: Patients with hepatopancreatobiliary cancer. Field Strength/Sequence: 31 P MRS. Assessment: The PubMed, EMBASE, and Cochrane library databases were systematically searched for studies published to 17 March 17, 2022. All 31 P MRS studies in hepatopancreatobiliary cancer reporting 31 P metabolite levels were included. Statistical Tests: Relative differences in 31 P metabolite levels/ratios between patients before therapy and healthy controls, and the relative changes in 31 P metabolite levels/ratios in patients before and after therapy were determined. Results: The search yielded 10 studies, comprising 301 subjects, of whom 132 (44%) healthy volunteers and 169 (56%) patients with liver cancer of various etiology. To date, 31 P MRS has not been applied in pancreatic cancer. In liver cancer, alterations in levels of 31 P metabolites involved in cell proliferation (phosphomonoesters [PMEs] and phosphodiesters [PDEs]) and energy metabolism (ATP and inorganic phosphate [Pi]) were observed. In particular, liver tumors were associated with elevations of PME/PDE and PME/Pi compared to healthy liver tissue, although there was a broad variety among studies (elevations of 2%-267% and 21%-233%, respectively). Changes in PME/PDE in liver tumors upon therapy were substantial, yet very heterogeneous and both decreases and increases were observed, whereas PME/Pi was consistently decreased after therapy in all studies (À13% to À76%). Data Conclusion: 31 P MRS has great potential for treatment monitoring in oncology. Future studies are needed to correlate the changes in 31 P metabolite levels in hepatopancreatobiliary tumors with treatment response.

show abstract

Metabolic changes underlying31P MR spectral alterations in human hepatic tumours

Bell

Bhakoo

1998

NMR Biomed.

View full text Add to dashboard Cite

Magnetic resonance spectroscopy (MRS) remains the technique of choice for observing tumour metabolism non‐invasively. Although initially 31P MR spectroscopy showed much promise as a non‐invasive diagnostic tool, studies of a wide range of hepatic tumours have conclusively shown that this technique cannot be utilized to distinguish between different tumour types. This lack of specificity and sensitivity appears to be a consequence of the fact that hepatic tumours develop with a range of modalities and not as a single abnormal disease process, and also because of the limited availability of MR detectable metabolic markers. This has led, in recent years, to a re‐evaluation of the role of 31P MR spectroscopy, re‐emerging as a non‐invasive tool to follow the efficacy of the treatment regime. Furthermore, since the principal changes observed in tumours by 31P MRS appear to be an elevation in the concentration of phosphorylcholine (PCho) and phosphoethanolamine (PEth), new research using a combination of MRS and tissue culture of cell lines which carry a combination of known inducible oncogenes, are helping to elucidate some of the metabolic pathways that give rise to these metabolic alterations. © 1998 John Wiley & Sons, Ltd.

show abstract

In Vivo P-31 -MR-Spectroscopy of Focal Hepatic Lesions

Cited by 9 publications

References 0 publications

Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver

Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver

Prospective of ³¹P MR Spectroscopy in Hepatopancreatobiliary Cancer: A Systematic Review of the Literature

Metabolic changes underlying31P MR spectral alterations in human hepatic tumours

Contact Info

Product

Resources

About

In Vivo P-31 -MR-Spectroscopy of Focal Hepatic Lesions

Cited by 9 publications

References 0 publications

Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver

Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver

Prospective of 31P MR Spectroscopy in Hepatopancreatobiliary Cancer: A Systematic Review of the Literature

Metabolic changes underlying31P MR spectral alterations in human hepatic tumours

Contact Info

Product

Resources

About

Prospective of ³¹P MR Spectroscopy in Hepatopancreatobiliary Cancer: A Systematic Review of the Literature